Related Experiment Video
Updated: Mar 23, 2026
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
Progress in Therapies for Myocardial Ischemia Reperfusion Injury
Hong-Jie Chi1,2, Mu-Lei Chen1, Xin-Chun Yang1,2
1Department of Cardiology, Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
Background:
Experimental studies of acute myocardial infarction have revealed that up to half of the final infarct size may be due to reperfusion injury rather than the initial ischemic incident. Research over the past three decades has deepened our understanding of the molecular mechanisms underlying ischemic reperfusion injury and several therapeutic strategies to decrease the incidence and severity of reperfusion injury have been explored.
Objective:
To discuss the promising therapies and future perspectives on methods to attenuate myocardial reperfusion injury.
Results:
Existing therapies that address reperfusion can be divided into two major groups comprising nonpharmacological and pharmacological interventions. Myriad pharmacological and nonpharmacological approaches to reduce lethal reperfusion injury have been employed. Although many initial clinical studies were negative, more recent proof-of-concept clinical trials are promising. To date, the most encouraging results are with ischemic postconditioning, remote ischemic preconditioning, ANP, adenosine, cyclosporine and exenatide.
Conclusion:
Studies demonstrate that nonpharmacological and pharmacological conditioning can be used together as part of a multifaceted approach to improve clinical outcomes in patients with ischemic heart disease.
Insights
Therapies targeting reperfusion injury, a major cause of heart attack damage, show promise. Combining non-pharmacological and pharmacological methods may improve outcomes for ischemic heart disease patients.
Area of Science:
- Cardiology
- Molecular Medicine
Background:
- Reperfusion injury significantly contributes to myocardial infarction size, sometimes accounting for up to 50% of the final infarct.
- Decades of research have elucidated molecular mechanisms of ischemic reperfusion injury, leading to exploration of therapeutic strategies.
Purpose of the Study:
- To review promising therapies and future directions for attenuating myocardial reperfusion injury.
- To provide an overview of current and emerging treatments for reducing heart muscle damage after reperfusion.
Main Methods:
- Review of existing non-pharmacological and pharmacological interventions for reperfusion injury.
- Analysis of clinical trial data, including recent proof-of-concept studies.
Main Results:
- Therapies for reperfusion injury fall into non-pharmacological and pharmacological categories.
- While early clinical studies yielded mixed results, recent trials show promise.
- Encouraging results observed with ischemic postconditioning, remote ischemic preconditioning, atrial natriuretic peptide (ANP), adenosine, cyclosporine, and exenatide.
Conclusions:
- Non-pharmacological and pharmacological conditioning strategies can be combined effectively.
- A multifaceted approach integrating conditioning methods can enhance clinical outcomes in patients with ischemic heart disease.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:14Myocarditis III: Medical Management
01:27Coronary Artery Disease V: Interprofessional Care
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:29Cardiomyopathy V: Interprofessional Care
01:17Pericarditis III: Medical Management